-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 13, Takeda announced that it would acquire NDI-034858
from Nimbus Therapeutics.
NDI-034858
is an orally selective allosteric tyrosine kinase 2 (TYK2) inhibitor that has been successful
in phase 2b clinical trials for psoriasis.
Upon completion of the transaction, NDI-034858 was codenamed Takeda
TAK-279
。
Under the terms of the agreement, Takeda will advance $4 billion to Nimbus and pay Nimbus $10 respectively after achieving annual net sales of $4 billion and $5 billion
Two milestone payments
for $100 million.
The advance payment will be provided primarily by cash on hand
.
The transaction is expected to close
by the end of fiscal year 2022.
Source: Takeda official website
Nimbus recently disclosed positive top-line results
from a Phase 2b study evaluating NDI-034858 in patients with moderate to severe plaque psoriasis.
Takeda plans to announce this in early 2023
Data from the Phase 2b study and advancing a Phase 3 clinical trial
of psoriasis in 2023.
From: Insight database (http://db.
dxy.
cn/v5/home/)
NDI-034858 is an allosteric TYK2 inhibitor developed by Nimbus Therapeutics and is being evaluated for its efficacy
in the treatment of a variety of autoimmune diseases.
From: Insight database (http://db.
dxy.
cn/v5/home/)
The two generations of JAK inhibitors currently on the market mainly inhibit JAK1, JAK2 and JAK3, but there are still some potential side effects
in both the first and second generations.
For example, a generation of tofacitinib and so on has "pan
JAK" phenomenon, second-generation upatinib and so on have a risk
of thrombosis.
As a result, many companies have turned their attention to TYK2
, which is also a member of the JAK kinase family.
TYK2 is involved in a variety of cytokines IL-23, IL-12, and type I IFN
and mediates downstream STAT phosphorylation
.
Functions
as a key regulator of cytokine signaling pathways in a variety of immune-mediated diseases such as psoriasis.
Original: _mstmutation="1" _msthash="220727" _msttexthash="19154421">
